1. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T (2009) HIV Clin Trials 10(3): 181-92
    › Primary publication · 19632957 (PubMed) · PMC2891063 (PubMed Central)
  2. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Canter JA, Haas DW, Kallianpur AR, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Murdock DG, Hulgan T (2008) Pharmacogenomics J 8(1): 71-7
    › Primary publication · 17684475 (PubMed)
  3. Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. Asad S, Hulgan T, Raffanti SP, Daugherty J, Ray W, Sterling TR (2008) J Natl Med Assoc 100(12): 1417-24
    › Primary publication · 19110909 (PubMed) · PMC3816354 (PubMed Central)
  4. Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic. Hulgan T, Klausner JD (2008) JAMA 299(12): 1426
    › Primary publication · 18364484 (PubMed)
  5. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. El-Bejjani D, Hazen SL, Mackay W, Glass NE, Hulgan T, Tungsiripat M, McComsey GA (2008) HIV Clin Trials 9(3): 207-11
    › Primary publication · 18547908 (PubMed) · PMC2829429 (PubMed Central)
  6. High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy. Hulgan T (2008) Evid Based Med 13(6): 183
    › Primary publication · 19043041 (PubMed)
  7. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams (2008) J Infect Dis 197(6): 858-66
    › Primary publication · 18419350 (PubMed)
  8. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. Oswald-Richter K, Grill SM, Leelawong M, Tseng M, Kalams SA, Hulgan T, Haas DW, Unutmaz D (2007) PLoS Pathog 3(4): e58
    › Primary publication · 17465678 (PubMed) · PMC1857714 (PubMed Central)
  9. Human genomic association studies: a primer for the infectious diseases specialist. Motsinger AA, Haas DW, Hulgan T, Ritchie MD (2007) J Infect Dis 195(12): 1737-44
    › Primary publication · 17492588 (PubMed)
  10. Agreement of decision analyses and subsequent clinical studies in infectious diseases. Bress JN, Hulgan T, Lyon JA, Johnston CP, Lehmann H, Sterling TR (2007) Am J Med 120(5): 461.e1-9
    › Primary publication · 17466659 (PubMed) · PMC1909755 (PubMed Central)